Ruijian Medicine Secures RMB 470 Million in Two Rounds Within a Month, Accelerating Innovation and Global Expansion

　　【Pharmaceutical Network - Corporate News】 Since 2026, investment enthusiasm in China’s pharmaceutical and health industry within the capital markets has continued to intensify. Data shows that in the first five months of 2026, the total financing and investment amount in the domestic primary healthcare market reached RMB 41.7 billion, a year-on-year increase of 57%. Among these, numerous companies have completed multiple rounds of financing, with individual funding amounts exceeding RMB 100 million.
 

On July 2, iRegene Therapeutics announced the completion of its C+ round financing, raising RMB 260 million. It is understood that the funds from this round will be primarily used to advance the company’s core clinical pipeline, support multi-pipeline clinical development, facilitate global registration and clinical operations, build industrialization systems, and carry out subsequent capitalization activities.
 

This financing marks another significant funding round completed by iRegene Therapeutics within a month, bringing the cumulative total from these two rounds to RMB 470 million. Specifically, in early June, iRegene Therapeutics announced the completion of its RMB 210 million Series C1 financing. The raised funds will be primarily used to advance the company’s core clinical pipeline, continuously upgrade its “AI + chemical induction” platform, build a large-scale production system, and expand global clinical development and international commercial partnerships.
 

Public information indicates that iRegene Therapeutics is an innovative pharmaceutical company focused on cell therapy and regenerative medicine, with its core business being the development of cell therapies for neurodegenerative diseases (such as Parkinson's disease) and ophthalmic diseases using "AI + chemical induction" technology.
 

Currently, the company is advancing clinical development of multiple pipelines in parallel in China and the United States. Its universal iPSC-derived dopaminergic neural progenitor cell therapy product for Parkinson’s disease, NouvNeu001, is concurrently conducting Phase II clinical trials in both countries. The first patient has been dosed at Weill Cornell Medicine in the United States, while five clinical centers in China have rapidly initiated patient enrollment. This product has also received dual designations from the U.S. FDA: Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT) designation. In addition, NouvNeu004, developed for multiple system atrophy with parkinsonism (MSA-P), has entered the clinical development stage.
 

Industry analysts believe that the successive completion of financing rounds fully demonstrates the capital market’s continued recognition of iRegene Therapeutics’ core clinical assets, multi-pipeline layout, industrialization foundation, and subsequent capitalization path. Following the completion of this Series C+ financing round, iRegene Therapeutics will focus on three core tasks: the release of clinical data, iteration of its technology platform, and improvement of its industrialization system, while continuously advancing global clinical development and overseas regulatory registration, and deepening international industrial cooperation.
 

Notably, to address its shortcomings in internationalization, iRegene Therapeutics has recently recruited Tim Ruan (Ruan Tianshi), a senior executive from the international capital markets, to oversee the company’s capital operations. Mr. Ruan previously served in the Capital Markets divisions of Goldman Sachs and Morgan Stanley, bringing extensive experience in cross-border investment banking, financing for innovative pharmaceutical companies, and engagement with global institutional investors.

 

In summary, iRegene Therapeutics has completed two consecutive rounds of substantial financing within one month, marking a critical phase in the company’s accelerated transition from “technology platform validation” to “clinical value realization,” thereby positioning it for broad long-term commercialization potential.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.